News
AACI Welcomes New Corporate Roundtable Members
AACI extends a warm welcome to its newest corporate members: AbbVie, Kite, and Pfizer. Launched in 2012, AACI's Corporate Roundtable creates opportunities for open discussion around important issues between industry representatives and leaders of academic cancer centers.
Founded in 2013 when it became a separate company from Abbott, AbbVie focuses on drug candidates that hold the potential to transform standard of care for patients with severe and life-threatening diseases.
Kite, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically-engineered autologous T-cell therapy with chimeric antigen receptors.
Pfizer’s core areas of interest include tumor cell biology, bioconjugates discovery and development, precision medicine, integrative biology and biochemistry, and immuno-oncology.
Working together, cancer centers and industry can leverage their mutual strengths to speed the development of promising therapies to the cancer patients served by AACI member centers. AACI is pleased to have these three new voices at the table. The new members join Amgen, Astellas, Bristol-Myers Squibb, Genentech, Janssen Oncology, Lilly, Merck, and Takeda Oncology on the Corporate Roundtable.
To learn more about corporate membership and AACI’s Corporate Roundtable partners, please contact Kate Burroughs, director of development, at 412-647-3844.
Founded in 2013 when it became a separate company from Abbott, AbbVie focuses on drug candidates that hold the potential to transform standard of care for patients with severe and life-threatening diseases.
Kite, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically-engineered autologous T-cell therapy with chimeric antigen receptors.
Pfizer’s core areas of interest include tumor cell biology, bioconjugates discovery and development, precision medicine, integrative biology and biochemistry, and immuno-oncology.
Working together, cancer centers and industry can leverage their mutual strengths to speed the development of promising therapies to the cancer patients served by AACI member centers. AACI is pleased to have these three new voices at the table. The new members join Amgen, Astellas, Bristol-Myers Squibb, Genentech, Janssen Oncology, Lilly, Merck, and Takeda Oncology on the Corporate Roundtable.
To learn more about corporate membership and AACI’s Corporate Roundtable partners, please contact Kate Burroughs, director of development, at 412-647-3844.